Biontech buys competitor Curevac:
Biontech acquires Curevac for around 1.25 billion dollars to develop innovative cancer therapies. The deal is expected to close ...
sueddeutsche.de/wirtschaft/biontech-curevac-biotech-branche-li.3268192
Photo: sueddeutsche.de · view article
Biontech Expands Through Curevac AcquisitionBiontech plans a $1.25B stock deal expected in 2025 to boost cancer immunotherapy development and unite mRNA expertise.
Key FactsJun 12, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: sueddeutsche.de
Summary created with AI assistance · Source: sueddeutsche.de
- Biontech is acquiring Curevac for approximately $1.25 billion to accelerate innovative cancer therapy research.
- The deal ends a long-standing rivalry peaked during the Covid-19 vaccine race between the two companies.
- The transaction is structured as a stock swap, granting Curevac shareholders four to six percent ownership in Biontech.
- Germany’s government views the acquisition favorably, highlighting the creation of a leading national biotech company.
We want to bring together complementary skills and technologies.— Uğur Şahin, co-founder and CEO of Biontech, discusses the goals of the acquisition of Curevac.
Story Details
| Last Updated | |
| Total Articles | 40 |
Main Topics
single unit of ownership in a corporation, mutual fund, or any other organization
News on this topic
Breaking news: Biontech plans to take over German competitor Curevac: The pharmaceutical company Biontech is planning to take over its German competitor Curevac ...
n-tv.de/newsletter/breakingnews/Biontech-will-deutschen-Konkurrenten-Curevac-uebernehmen-article25829589.html
BioNTech Acquires CureVac: On the Way to Global Power in Cancer Medicine: The acquisition of CureVac is one of a series of major deals. They are intended to make ...
wiwo.de/unternehmen/industrie/biontech-uebernimmt-curevac-auf-dem-weg-zur-globalen-macht-in-der-krebsmedizin/100134721.html
Paid articlePaywall
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals: German biotech firm BioNTech has agreed to acquire domestic peer CureVac for ...
reuters.com/business/healthcare-pharmaceuticals/biontech-acquire-curevac-125-billion-all-stock-deal-2025-06-12/
More articles on this subject
Previous
Mainz-based company BioNTech wants to acquire CureVac from Tübingen: The Mainz-based pharmaceutical company BioNTech wants to acquire its rival CureVac from ...
swr.de/swraktuell/biontech-mainz-will-uebernahme-curevac-tuebingen-100.html
Biontech buys competitor Curevac: Biontech acquires Curevac for around 1.25 billion dollars to develop innovative cancer therapies. The deal is expected to close ...
sueddeutsche.de/wirtschaft/biontech-curevac-biotech-branche-li.3268192
Biontech's oncology strategy: Curevac to follow after Biotheus takeover: Biontech wants to buy its competitor Curevac from Tübingen. The location will continue ...
heise.de/news/Onkologie-Strategie-Nach-Uebernahme-von-Biotheus-will-Biontech-Curevac-kaufen-10443873.html
Pharmaceutical industry: BioNTech wants to take over competitor Curevac: The pharmaceutical company BioNTech intends to purchase all shares of Curevac ...
zeit.de/wirtschaft/2025-06/pharmaindustrie-deutschland-biontech-curevac-uebernahme
OpinionTübingen-based company Curevac: The sale is also a cause for sadness: It is the end of a company history that is not exactly short of highs and lows: The once ...
swp.de/lokales/tuebingen/kommentar-man-darf-auch-etwas-traurig-sein-78117430.html
Paid articlePaywall
BioNTech after the CureVac deal: Target price $140: BioNTech plans acquisition of CureVac; Deutsche Bank recommends buy with target $140 ...
deraktionaer.de/artikel/pharma-biotech/biontech-nach-dem-curevac-deal-kursziel-140-dollar-20381748.html
Offer from Biontech - | This is what Curevac CEO Zehnder says about the planned takeover
stuttgarter-nachrichten.de/inhalt.angebot-von-biontech-das-sagt-curevac-chef-zehnder-zur-geplanten-uebernahme.d8f1f762-0383-4197-82f5-69018c8eaac0.html
Paid articlePaywall
Biontech and Curevac: Planned merger is a clever solution: The planned merger of Biontech and Curevac is a clever solution that will save face for both the mRNA ...
faz.net/aktuell/wirtschaft/mehr-wirtschaft/biontech-und-curevac-geplante-fusion-ist-clevere-loesung-110533140.html
The background to the mega-merger: BioNTech wants to take over rival CureVac: BioNTech is planning to take over rival CureVac - | probably also to gain expertise ...
businessinsider.de/wirtschaft/die-hintergruende-zu-der-mega-fusion-im-gesundheitswesen-biontech-will-rivalen-curevac-uebernehmen/
German pharmaceutical deal - | Biontech is going after Curevac: Once considered great biotech hopes, both were in a head-to-head race for the coronavirus vaccine ...
remszeitung.de/baden-wuerttemberg/deutscher-pharmadeal-biontech-greift-nach-curevac-47EQ5E7LKOF2KIDTCACLFYPYFE.html
Covid-19 vaccine-maker BioNTech to acquire former rival CureVac: Both German companies have continued mRNA programs on so-called cancer vaccines.
politico.eu/article/covid-19-vaccine-maker-biontech-to-acquire-former-rival-curevac/
Marburg: BioNTech wants to acquire Tübingen-based pharmaceutical company CureVac: Both were once considered great biotech hopefuls, they were in a neck-and-neck ...
op-marburg.de/lokales/marburg-biedenkopf/marburg/marburg-biontech-will-tuebinger-pharmaunternehmen-curevac-uebernehmen-C5DTT2ATEJG43CDJHASCYTPFYI.html
German pharmaceutical deal: Biontech reaches out to Curevac - | Deutsches Ärzteblatt
aerzteblatt.de/news/deutscher-pharmadeal-biontech-greift-nach-curevac-3cbfc6a2-7a99-4005-9d78-a25d9bbc1965
Billion-euro deal: pharmaceutical company Biontech swallows competitor Curevac: Biontech is taking over Curevac for 1.25 billion dollars. The company explained ...
berliner-zeitung.de/news/milliarden-deal-pharmaunternehmen-biontech-schluckt-konkurrent-curevac-li.2332841
BioNTech plans to take over Tübingen-based pharmaceutical company CureVac - | Business News - | Reutlinger General-Anzeiger - | gea.de
gea.de/neckar-alb/wirtschaft-in-der-region_artikel,-biontech-will-t%C3%BCbinger-pharmaunternehmen-curevac-%C3%BCbernehmen-_arid,7040500.html
dpaq.de Jun 12 25
Vaccine maker BioNTech to acquire fellow German pharma firm CureVac: BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine ...
nordot.app/1305853995084316790
Pharmaceutical company - | BioNTech wants to take over competitor CureVac: Both were once considered great biotech hopes, they were in a neck-and-neck race for ...
stuttgarter-nachrichten.de/inhalt.pharmaunternehmen-biontech-will-konkurrenten-curevac-uebernehmen.b173202c-095a-4c14-b6f4-217bd0fbf513.html
Biotech: Biontech buys Curevac: Tübingen company is to be completely absorbed into Biontech. The name is to disappear. The acquisition is intended to boost ...
swp.de/wirtschaft/biotech-biontech-kauft-curevac-78116999.html
Biontech buys Curevac: Biotech champion to advance the fight against cancer: Biontech is paying around 1.25 billion dollars for its competitor Curevac ...
handelsblatt.com/unternehmen/industrie/biontech-kauft-curevac-biotech-champion-soll-kampf-gegen-krebs-vorantreiben/100134645.html
Paid articlePaywall
Pharmaceutical deal hammer: Biontech wants to take over German competitor Curevac
focus.de/finanzen/biontech-will-deutschen-konkurrenten-curevac-uebernehmen_af5d792a-c419-4fed-b23b-4f8573d1620b.html
Barron's Jun 12 25
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.: CureVac stock soared after BioNTech said it would buy the smaller biotech for for $1 ...
barrons.com/articles/biontech-curevac-buy-deal-c5d999c4
Paid articlePaywall Takeover planned: Biontech wants to buy Curevac: They were rivals during the pandemic, and they are fighting in court over patents and billions ...
faz.net/aktuell/wirtschaft/uebernahme-geplant-biontech-will-curevac-kaufen-110532036.html
Biontech acquires competitor Curevac: Billion-dollar deal: The Mainz-based biopharmaceutical company Biontech is acquiring the Tübingen-based biotech company ...
main-spitze.de/wirtschaft/wirtschaft-deutschland/biontech-uebernimmt-den-konkurrenten-curevac-4709665
Biontech takes over competitor Curevac: Billion-dollar deal: The Mainz-based biopharmaceutical company Biontech is swallowing the Tübingen-based biotech company ...
wiesbadener-kurier.de/wirtschaft/wirtschaft-deutschland/biontech-uebernimmt-den-konkurrenten-curevac-4709665
BioNTech takes over competitor CureVac: Billion-dollar deal: The Mainz-based biopharmaceutical company BioNTech is acquiring the Tübingen-based biotech company ...
echo-online.de/wirtschaft/wirtschaft-deutschland/biontech-uebernimmt-den-konkurrenten-curevac-4709665
Biontech acquires competitor Curevac: Billion-dollar deal: The Mainz-based biopharmaceutical company Biontech is acquiring the Tübingen-based biotech company ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-deutschland/biontech-uebernimmt-den-konkurrenten-curevac-4709665
Next
Similar to This
Previous
Film about Ingmar Hoerr and CureVac in Tübingen: Saving the world in a flash: A biopic about mRNA pioneer and CureVac founder Ingmar Hoerr premieres at the Hof ...
swp.de/lokales/tuebingen/kultur-tuebingen/film-ueber-curevac-in-tuebingen-mal-eben-kurz-die-welt-retten-79556685.html
Paid articlePaywall OpinionMillion-dollar bonuses: Boris Palmer rants: Payments to CureVac manager "outrageous"
stuttgarter-nachrichten.de/wirtschaft/millionen-boni-boris-palmer-empoerend-hohe-zahlungen-an-curevac-manager-79539819.html
BioNTech: Three German sites are closing their plants: No buyer has been found for the plants in Idar-Oberstein, Marburg, and Tübingen. BioNTech has announced ...
handelsblatt.com/unternehmen/industrie/biontech-drei-deutsche-standorte-schliessen-ihre-werke/100257969.html
Paid articlePaywallKey FactsBiontech announces closure of three sites from 2027
Sep 29, 2026 · Reading time: ~30 sec.
Summary created with AI assistance · Source: handelsblatt.com
Summary created with AI assistance · Source: handelsblatt.com
- The closures are scheduled for Tübingen in late 2027, Marburg in early 2028 and Idar-Oberstein in late 2028.
- According to the company, the decision affects about 1,800 employees, nearly one-quarter of Biontech’s workforce.
- Biontech attributed the failed months-long search mainly to difficult market and investment conditions.
- Biontech agreed additional severance terms with the group works council, but initially disclosed no details.
"That's impossible": BioNTech breaks promises - | 1,800 people lose their jobs in Germany
op-online.de/wirtschaft/biontech-schliesst-drei-standorte-1800-jobs-weg-kein-kaeufer-gefunden-zr-94518629.html
Exclusive: Federal government wants to sell off all BioNTech shares it holds: Since BioNTech acquired CureVac, the federal government has held shares in the ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/exklusiv-bundesregierung-stoesst-alle-biontech-aktien-ab-6476398
Paid articlePaywall CureVac in Tübingen: Takeover by BioNTech and sites in danger: BioNTech acquired CureVac for $1.25 billion at the end of last year and will now close all CureVac ...
sueddeutsche.de/wirtschaft/ugur-sahin-oezlem-tuereci-ingmar-hoerr-struengmann-mrna-impfstoffe-mrna-krebs-moderna-li.3522088
Paid articlePaywallWill the Tübingen site be completely closed?: Clarity on BioNTech locations by the end of September
swp.de/lokales/tuebingen/tuebinger-standort-bedroht-klarheit-ueber-biontech-standorte-bis-ende-september-79418978.html
BioNTech closes CureVac site in Tübingen: What happened to 300 million euros of taxpayers' money
op-online.de/wirtschaft/curevac-und-biontech-wie-der-impfstoff-traum-der-merkel-aera-endet-zr-94355314.html
CureVac exit threatens Tübingen as a research location - | Tübingen district - | Reutlinger General-Anzeiger - | gea.de
gea.de/neckar-alb/kreis-tuebingen_artikel,-curevac-aus-bedroht-t%C3%BCbingen-als-forschungsstandort-_arid,7153598.html
Pharmaceutical industry: CureVac founder accuses BioNTech of deception: Shortly after the acquisition, BioNTech announced the closure of CureVac's former ...
zeit.de/wirtschaft/unternehmen/2026-05/curevec-gruender-vorwurf-taeuschung-biontech
Bayer Group surprisingly sues Mainz-based BioNTech - | here's the background: No sooner has the patent dispute with CureVac been settled through the takeover ...
mittelhessen.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/bayer-verklagt-ueberraschend-biontech-was-ist-da-los-5297243
Paid articlePaywall Biotech: BioNTech finalizes CureVac acquisition: The merger of the two vaccine developers is complete. BioNTech is acquiring its competitor CureVac - | and thus ...
handelsblatt.com/unternehmen/industrie/biotech-biontech-macht-uebernahme-von-curevac-perfekt/100185010.html
BioNTech stock: Hope is back: BioNTech acquires CureVac and strengthens market position; blockbuster potential for new cancer drug BNT327.
boerse-online.de/nachrichten/aktien/biontech-aktie-die-hoffnung-ist-zurueck-20392023.html
80 percent of shares acquired: CureVac billion-euro deal with BioNTech close to completion
swp.de/lokales/tuebingen/80-prozent-der-aktien-uebernommen-curevac-milliarden-deal-mit-biontech-kurz-vor-abschluss-78493611.html
Share swap - | Biontech launches offer to Curevac shareholders: The deadline for the share swap is December 3rd. The former competitors plan to conduct joint ...
stuttgarter-nachrichten.de/inhalt.aktientausch-biontech-startet-angebot-an-curevac-aktionaere.9753c233-bf64-4877-8fed-36fe7b77f02d.html
Antitrust authority approves BioNTech's acquisition of CureVac: Why do competition watchdogs see no threat to innovation in the merger between BioNTech and ...
giessener-allgemeine.de/wirtschaft/kartellamt-erlaubt-kauf-von-curevac-durch-biontech-zr-93985421.html
Curevac and Biontech end dispute: Agreement thanks to takeover: Curevac and its partner GSK will receive a total of 740 million euros for the rights to Covid-19 ...
swp.de/lokales/tuebingen/curevac-und-biontech-beenden-streit-einigung-dank-uebernahme-78234691.html
Paid articlePaywall Pharma industry: Biontech halves loss - cancer strategy picks up speed: Biontech more than doubled its turnover in the second quarter. The company plans to spend ...
handelsblatt.com/unternehmen/industrie/pharmaindustrie-biontech-halbiert-verlust-krebsstrategie-nimmt-fahrt-auf/100146054.html
Key FactsBiontech Boosts Growth with Cancer Strategy and Deals
Aug 4, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: handelsblatt.com
Summary created with AI assistance · Source: handelsblatt.com
- Biontech doubled its revenue to €260.8 million in Q2 and reduced its net loss to €386.6 million.
- The company is refocusing on oncology, strengthened by a partnership with Bristol Myers Squibb and the planned acquisition of Curevac.
- Over 20 studies involving BNT327 across various tumors are underway, with a pivotal breast cancer phase-3 study starting this year.
- Revenue is forecasted to decline in 2025 while R&D spending is expected to increase to as much as €2.8 billion.
We continue to invest significantly in the implementation of our strategy, and our operational and financial measures are showing initial tangible results.— CFO Ramón Zapata discusses Biontech's progress in cancer research.
Biontech swallows Curevac: A billionaire paves the way: No question: Biontech has pulled off a coup with the takeover of Curevac. But what prompted Curevac to ...
mittelhessen.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/biontech-schluckt-curevac-ein-milliardaer-macht-den-weg-frei-4722890
Paid articlePaywallKey FactsBiontech Acquires Curevac with Billionaire Support
Jun 18, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: mittelhessen.de
Summary created with AI assistance · Source: mittelhessen.de
- Biontech finalized the acquisition of Curevac in June 2025, expanding its capabilities in RNA technology.
- SAP billionaire Dietmar Hopp holds over one-third of Curevac shares through investment firms, facilitating the transaction.
- The takeover is viewed by Biontech as a key element in enhancing its oncology strategy and future cancer therapies.
- Curevac founder Ingmar Hoerr expressed regret that the Curevac brand will disappear following the acquisition.
This transaction is another building block in Biontech's oncology strategy and an investment in the future of cancer medicine.— Ugur Sahin, CEO and co-founder of Biontech, discussing the significance of the acquisition of Curevac.
patent lawsuit - Court case between Curevac and Biontech begins: The patent process between Curevac and Biontech has started before the Düsseldorf district court ...
stuttgarter-nachrichten.de/inhalt.patentklage-gerichtsprozess-zwischen-curevac-und-biontech-beginnt.969f6b85-17d5-4a3d-9d6b-fc2552aed5df.html
Key FactsCovid-19 Vaccine Patent Dispute Enters Court Phase
Aug 15, 2023 · Reading time: ~45 sec.
Summary created with AI assistance · Source: stuttgarter-nachrichten.de
Summary created with AI assistance · Source: stuttgarter-nachrichten.de
- The lawsuit at Düsseldorf Regional Court addresses alleged intellectual property infringements between Curevac and Biontech regarding Covid-19 vaccines.
- Curevac claims compensation, asserting it developed key technologies essential to vaccine creation.
- Biontech rejects these accusations, maintaining that its work is original and independently developed.
- The court aims to rule on four of five issues by late September, awaiting a Federal Patent Court decision on the remaining matter by December.
We will vigorously defend ourselves against all allegations of patent infringement.— BioNTech; the company said this shortly after the complaint became known.
Next